Press Releases

Results of New Meta-Analysis Further Demonstrate Safety Profile and Robust Efficacy of EndoBarrier® Therapy in Patients with Type 2 Diabetes and Obesity

Accumulated Clinical Experience across Four International Studies Highlighted in Two Presentations at World IDF Congress  LEXINGTON, Massachusetts & MELBOURNE, Australia – 3 December 2013 – GI Dynamics, Inc. (ASX: GID) today announced findings from a new meta-analysis which describes the...

read more

GI Dynamics Announces EndoBarrier® Therapy Data to be Presented at International Diabetes Foundation World Diabetes Conference

LEXINGTON, Massachusetts and SYDNEY, Australia – 26 November 2013 – GI Dynamics, Inc. (ASX: GID) announced today that data on EndoBarrier® Therapy will be presented during two sessions at the International Diabetes Federation (IDF) World Diabetes Congress taking place in Melbourne, Australia on...

read more

GI Dynamics Announces EndoBarrier® Therapy Data to be Presented at Obesity Week

LEXINGTON, Massachusetts and SYDNEY, Australia – 12 November 2013 – GI Dynamics, Inc. (ASX: GID) announced today that data on EndoBarrier® Therapy will be presented during three sessions at Obesity Week, taking place in Atlanta, Ga., November 11-16, 2013. This event is a combined annual meeting of...

read more

GI Dynamics to Participate in Diabetes Treatment Panel Discussion at Cleveland Clinic’s 11th Annual Medical Innovation Summit

LEXINGTON, Massachusetts & SYDNEY, Australia – 9 October 2013 – GI Dynamics, Inc. (ASX: GID) announced today that Stuart A. Randle, president and chief executive officer, was invited to participate in the Cleveland Clinic’s 11th Annual Medical Innovation Summit, “Finding Balance through...

read more

EndoBarrier® Therapy Receives OPS Codes in Germany and Switzerland

LEXINGTON, Massachusetts & SYDNEY, Australia – 1 October 2013 – GI Dynamics, Inc. (ASX: GID) announced today that the German Institute of Medical Documentation and Information (DMDI) has designated preliminary OPS codes (Operationen- and Prozedurenschlussel) to EndoBarrier® Therapy which is...

read more

Clinical Research Findings Presented at European Diabetes Meeting Reinforce Efficacy of EndoBarrier® Therapy in Treatment of Type 2 Diabetes

Data from two patient registries in commercialized markets, clinical research and a meta-analysis of 13 clinical studies highlighted in four presentations at EASD LEXINGTON, Mass. & BARCELONA, Spain – 25 September 2013 – GI Dynamics, Inc. (ASX: GID) announced today that EndoBarrier® Therapy...

read more

GI Dynamics Reports on Recent EndoBarrier® Therapy Clinical Highlights and Activities

LEXINGTON, Mass. and SYDNEY – 17 September 2013 – GI Dynamics, Inc. (ASX: GID) today announced recent clinical research presentations and peer-reviewed publications about EndoBarrier® Therapy and an update from the successful, inaugural meeting of its European Union Advisory Board. “The...

read more

GI Dynamics, Inc. Provides Update on Progress of the ENDO Trial

LEXINGTON, Massachusetts & SYDNEY – 12 September 2013 – GI Dynamics, Inc. (ASX: GID) today announced an update on the progress of the ENDO Trial, its U.S. multi-center, pivotal clinical trial of EndoBarrier® for the treatment of patients who have uncontrolled type 2 diabetes and obesity. To...

read more

Association of British Clinical Diabetologists Funds and Initiates National Health Service Supported Study of EndoBarrier® Therapy in the United Kingdom

REVISE-Diabesity to Evaluate EndoBarrier Therapy in Patients with Uncontrolled Type 2 Diabetes and Obesity  LEXINGTON, Massachusetts & SYDNEY – 10 September 2013 – GI Dynamics, Inc. (ASX: GID) today announced that the Association of British Clinical Diabetologists (ABCD) has initiated an open...

read more

GI Dynamics to Present at Canaccord Genuity 33rd Annual Growth Conference

LEXINGTON, Massachusetts and SYDNEY – 8 August 2013 – GI Dynamics, Inc. (ASX: GID), announced today that management will present at the Canaccord Genuity 33rd Annual Growth Conference to be held August 14-15, 2013, at the InterContinental Hotel in Boston. Stuart A. Randle, president and chief...

read more
Page 1 of 3123